Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:activeIngredient |
gptkb:palonosetron
|
| gptkbp:approvalYear |
2003
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
A04AA05
|
| gptkbp:brand |
gptkb:palonosetron
|
| gptkbp:CASNumber |
135729-62-3
|
| gptkbp:chemicalFormula |
C19H24N2O
|
| gptkbp:contraindication |
hypersensitivity to palonosetron
|
| gptkbp:drugClass |
5-HT3 antagonist
|
| gptkbp:halfLife |
about 40 hours
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aloxi
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
Helsinn Healthcare
|
| gptkbp:routeOfAdministration |
intravenous
|
| gptkbp:sideEffect |
constipation
fatigue headache |
| gptkbp:usedFor |
prevention of postoperative nausea and vomiting
prevention of chemotherapy-induced nausea and vomiting |
| gptkbp:bfsParent |
gptkb:Takeda
|
| gptkbp:bfsLayer |
6
|